Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Biogen Idec fell $3.72 (-1.3%) to $287.12 on average volume. Throughout the day, 1,397,657 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,813,300 shares. The stock ranged in price between $281.32-$291.56 after having opened the day at $285.00 as compared to the previous trading day's close of $290.84. Other companies within the Drugs industry that declined today were:

Synthetic Biologics



), down 30.9%,

Auxilium Pharmaceuticals



), down 17.7%,




), down 15.8% and

Usana Health



), down 15.7%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $67.2 billion and is part of the health care sector. The company has a P/E ratio of 45.1, above the S&P 500 P/E ratio of 17.7. Shares are up 4.0% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Biogen Idec

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front,

AVANIR Pharmaceuticals



), up 45.6%,

Adamas Pharmaceuticals



), up 15.3%,

22nd Century Group



), up 14.0% and

Supernus Pharmaceuticals



), up 8.4% , were all gainers within the drugs industry with




) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.